CVC faces investor revolt over €10.7 billion Recordati deal
CVC is facing opposition from shareholders over its proposed €10.7 billion take-private of Italian pharmaceutical company Recordati. Investors accuse the private-equity group of pressuring them to sell at a price they consider too low. The Financial Times RSS summary does not state how much stock opponents control or whether CVC plans to revise its offer.
Why it matters
Shareholder resistance could complicate one of Europe's larger private-equity transactions and test the buyer's pricing power.
Sources
finite. summarises the reporting above and links to each original. We do not reproduce full articles. Read the sources for complete coverage.
Part of the September 13, 2026 brief.